

ASSIGNMENT

WHEREAS, **CHATTEM, INC.**, hereinafter referred to as the ASSIGNOR, a corporation of New Jersey, having its principal place of business at 55 Corporate Drive, Bridgewater, NJ 08807 is the owner of certain inventions or improvements entitled "PARABEN-FREE FEXOFENADINE FORMULATIONS" for which applications for Letters Patent have been made in the following Patent Office(s) and as listed on Attachment A hereto (hereafter Patent Property):

USPTO on 20 January, 2023, as US Provisional Patent Application No. 63/440,356

WHEREAS, **OPELLA HEALTHCARE GROUP SAS**, hereinafter referred to as the ASSIGNEE, a corporation of France, having its principal place of business at 82 AVENUE RASPAIL, 94250 GENTILLY, FRANCE, is desirous of acquiring the entire right, title, and interest in and to the said Patent Property in any and all countries;

NOW, THEREFORE, for good and valuable consideration, the receipt of which is acknowledged, and intending to be legally bound thereby, effective as of July 1, 2021, ASSIGNOR has sold, assigned, transferred and set over to said ASSIGNEE, the entire right, title and interest, including the right to claim priority, in and to said Patent Property and any and all continuations, divisions and renewals of and substitutes for said Patent Property and to and under any and all additional Letters Patent which may be granted on or as a result thereof in the United States and any and all other countries, and any reissue or reissues or extension or extensions of said Letters Patent, and the full right to sue for and recover damages recoverable for past infringement of the same, and for violations of provisional rights having arisen from any published application(s) for said Patent Property. ASSIGNOR further assigns to and authorizes said ASSIGNEE to file corresponding applications for Letters Patent in all countries, to be held and enjoyed by said ASSIGNEE, its successors, assigns, nominees or legal representatives, to the full end of the term or terms for which said Letters Patent respectively may be granted, reissued or extended, as fully and entirely as the same would have been held and enjoyed by ASSIGNOR had this assignment, sale and transfer not been made.

It is hereby covenanted that effective July 1, 2021, ASSIGNOR has full right to convey the assigned entire interest in the patent applications listed herein, and that ASSIGNOR has not executed and will not execute any agreement in conflict herewith, and ASSIGNOR further covenants and agrees that it will each time request is made and without undue delay, execute and deliver all such papers as may be necessary or desirable to perfect the title to said Patent Property in said assignee, its successors, assigns, nominees, or legal representatives, and ASSIGNOR agrees to communicate to said ASSIGNEE or to its nominee all known facts respecting said Patent Property, to testify in any legal proceedings, to sign all lawful papers to execute all disclaimers and divisional, continuing, reissue and foreign applications, to make all rightful oaths, and generally to do everything reasonably possible to aid said ASSIGNEE, its successors, assigns, nominees and legal representatives to obtain and enforce for its or their own benefit proper patent protection for said inventions or improvements in any and all countries, all at the expense, however, of said ASSIGNEE, its successors, assigns, nominees or legal representatives.

AND ASSIGNOR hereby authorizes and requests the Commissioner of Patents and Trademarks of the United States and any official of any country or countries foreign to the United

States whose duty it is to issue patents on applications as aforesaid, to issue to said ASSIGNEE, as assignee of the entire right, title and interest, any and all Letters Patent for said Patent Property, including any and all Letters Patent of the United States which may be issued and granted on or as a result of any applications included in said Patent Property, in accordance with the terms of this assignment.

IN WITNESS WHEREOF, the undersigned, being properly authorized to execute this Assignment, hereunto sets their hand and seal.

CHATTEM, INC.

By:

DocuSigned by:



7641391427C14B6...

Name: Rabiya Kader

Title: Global Head of IP Sanofi
Consumer Healthcare

s

Date: 5/22/2023

OPELLA HEALTHCARE GROUP SAS

By:

DocuSigned by:



7641391427C14B6...

Name: Rabiya Kader

Title: Global Head of IP Sanofi
Consumer Healthcare

s

Date: 5/22/2023

ATTACHMENT A

Country	Our Reference	Application No.	Filing Date	Title
US	070589.12777-P187US1	63/440,356	01-20-2023	Paraben-Free Fexofenadine Formulations